Alx Oncology Holdings INC Form 4 insider transactions

Chief Medical Officer Alan B. Sandler reports the acquisition of stock options in ALX Oncology Holdings Inc.

Harish Shantharam, CFO of ALX Oncology Holdings Inc, reports the acquisition of stock options.

ALX Oncology Holdings CEO Jason Lettmann reports acquisition of 125,000 employee stock options on April 11, 2025.

Shelly Pinto, SVP, Finance and CAO of ALX Oncology Holdings Inc., acquired 3,000 shares of common stock on March 14, 2025, following the achievement of performance metrics related to the ASPEN-06 clinical trials.

ALX Oncology's CEO, Jason Lettmann, acquired 42,000 shares of common stock on March 14, 2025, following the achievement of performance metrics related to positive results from the ASPEN-06 clinical trials.

Shelly Pinto, SVP, Finance and CAO of ALX Oncology Holdings Inc., sold 550 shares of common stock on February 19, 2025, to cover tax obligations related to vesting restricted stock units.

Jaume Pons, President & CSO of ALX Oncology Holdings Inc., sold 1,326 shares of common stock on February 19, 2025, to satisfy tax obligations related to vesting restricted stock units.

ALX Oncology's CEO, Jason Lettmann, sold 2,159 shares of common stock on February 19, 2025, to cover tax liabilities related to vesting restricted stock units.

Rekha Hemrajani, a director at ALX Oncology Holdings Inc., was granted stock options for 40,400 shares at an exercise price of $1.65.

Director Scott Garland acquired 40,400 shares of ALX Oncology through an option grant, vesting monthly starting February 21, 2025.

Corey Goodman, a director at ALX Oncology Holdings Inc., was granted stock options for 40,400 shares at an exercise price of $1.65.

Chris H. Takimoto, a director at ALX Oncology Holdings Inc., acquired stock options for 40,400 shares of common stock.

Director Barbara Klencke of ALX Oncology Holdings Inc. was granted stock options for 40,400 shares on January 21, 2025.

ALX Oncology's Chief Financial Officer, Harish Shantharam, was granted 600,000 stock options on January 21, 2025.

Shelly Pinto, SVP of Finance and CAO at ALX Oncology Holdings Inc., was granted 112,000 stock options on January 21, 2025, which vest over 48 months.

Alan Sandler, Chief Medical Officer of ALX Oncology Holdings Inc., was granted 100,000 stock options on January 21, 2025, according to a recent SEC filing.

Jaume Pons, President & CSO of ALX Oncology Holdings Inc., was granted 50,000 employee stock options.

ALX Oncology's CEO, Jason Lettmann, was granted 478,000 stock options, vesting monthly over four years, according to a recent SEC filing.

Shelly Pinto, Interim CFO of ALX Oncology Holdings Inc., sold 2,221 shares of common stock to cover tax obligations related to vesting restricted stock units.

Shelly Pinto, Interim CFO of ALX Oncology Holdings Inc., sold 1,426 shares of common stock on December 30, 2024, to satisfy tax obligations related to vesting restricted stock units.

Jaume Pons, President and CSO of ALX Oncology Holdings Inc., sold 10,796 shares of common stock to cover tax obligations related to vesting restricted stock units.

Director Rekha Hemrajani of ALX Oncology Holdings Inc. purchased 30,000 shares of common stock at a weighted average price of $1.5468 per share.

Shelly Pinto, Interim CFO of ALX Oncology Holdings Inc., was granted 150,000 stock options on December 2, 2024, according to a recent SEC filing.

ALX Oncology's CEO, Jason Lettmann, was granted 200,000 stock options on December 2, 2024, which vest over 30 months starting January 2, 2025.

Alan B. Sandler, Chief Medical Officer of ALX Oncology Holdings Inc., was granted 600,000 employee stock options on November 18, 2024.

Shelly Pinto, SVP, Finance and CAO of ALX Oncology Holdings Inc., sold 564 shares of common stock on August 14, 2024, to cover tax obligations related to vesting restricted stock units.

Sophia Randolph, Chief Medical Officer of ALX Oncology Holdings Inc., sold 1,365 shares of common stock on August 14, 2024, to satisfy tax obligations related to vesting restricted stock units.

Peter Garcia, CFO of ALX Oncology Holdings Inc., reports the disposal of 761 common stock shares to cover tax obligations related to vesting restricted stock units.

Jaume Pons, President & CSO of ALX Oncology Holdings Inc., sold 1,937 shares of common stock on August 14, 2024, to satisfy tax obligations related to vesting restricted stock units.

CEO Jason Lettmann of ALX Oncology Holdings Inc. reports the disposal of shares to cover tax obligations related to vested restricted stock units.